Phase 1/2 Study of HQK-1001 in Patients With Beta Thalassemia

Summary

The purpose of this study is to evaluate the safety and tolerability of HQK-1001 administered daily for 8 weeks in subjects with beta thalassemia intermedia

Timeline

Start

2009-03

Primary completion

2010-05

Completion

2010-05

Outcome

Results reported · no primary-endpoint met/missed verdict (typical of a dose-finding / safety study)

paper The study of the four different doses of HQK-1001 did not report results for either haemoglobin or HbF. PMID 36637054 ↗

Publications

• Foong WC, Loh CK, Ho JJ, Lau DS. Foetal haemoglobin inducers for reducing blood transfusion in non-transfusion-dependent beta-thalassaemias. Cochrane Database Syst Rev. 2023 Jan 13;1(1):CD013767. doi: 10.1002/14651858.CD013767.pub2.

Drugs

Indications